Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

Adam Boehler was one of very few VC-backed founders who joined the Trump administration, leaving Landmark Health in 2018 to become director of the Center for Medicare and Medicaid Innovation. Now he's back in the private sector, with a new startup that wants to disrupt the kidney care market.

Why it matters: The CDC estimates that 15% of U.S. adults suffer from some form of chronic kidney disease, including more than 38% of those over 65 years old.

  • There are plenty of businesses servicing this population, including a pair of publicly traded dialysis center giants. But Boehler argues they're too focused on fees, and too little on helping patients get at-home treatments or kidney transplants.
  • It's a case that's been made by several academic nephrology centers, with which Boehler says he wants to partner. It's also reminiscent of Landmark Health, which focused on at-home medical services and which was bought earlier this year by a UnitedHealth subsidiary for billions of dollars.

The new company is called Evergreen Health, and will be publicly unveiled later Tuesday.

  • It's under the umbrella of a healthcare incubator called Rubicon Founders, which Boehler recently formed with an undisclosed amount of funding from Oak HC/FT and Welsh, Carson, Anderson & Stowe. At least $25 million is being dedicated to Evergreen's launch.

Lessons learned: Boehler says his big takeaway from Landmark Health was that physicians will change their behavior if compensation is linked more to patient outcomes than to their procedures.

  • "We told physicians that we were going to pay them very well, but pay them very well for treating patients the way they wanted to when they went to medical school ... Who gives a shit how many patients you can see in a day at a dialysis center? Instead of seeing 20 patients, see three and get them to a place where they can be treated at home or get a transplant."
  • Boehler, who also served as the first-ever CEO of the U.S. International Development Finance Corp., adds that his big lesson from government was that it has a lot more smart and talented people than he realized while in the private market, and says "there's no platform like it in terms of making an impact if you're willing to lean in."

Look ahead: Expect Rubicon Founders to continue launching new companies focused on health markets that it considers to have at least $1 billion of value opportunity.

Go deeper

Tech founders have left the building

Illustration: Aïda Amer/Axios

Most of today's tech giants are no longer run by their founders, but by a new breed of successor CEOs tasked with holding true to a corporate mission while continuing to pump up growth.

The big picture: Silicon Valley has long embraced a "founders know best" philosophy. But eventually, most successful founders get old and tired and rich — and lose interest in the meetings, the management messes, and the sheer hard work of running a company.

Businesses grapple with vax mandates and COVID policies

Illustration: Sarah Grillo/Axios

A growing number of U.S. companies have mandated COVID-19 vaccinations for employees. But in the absence of a federal mandate there's a wide variance in what’s happening — mandates for all, some, or none — with employee demands being put front and center thanks to the Great Resignation.

Why it matters: How companies answer questions about vaccines and return-to-work policies has wide ranging impacts — on the health of their employees, on where people live, and on the strategic direction of their businesses.

Tina Reed, author of Vitals
4 hours ago - Health

FDA panel endorses shot of J&J booster for adults

Photo: Wolfgang Kumm/picture alliance via Getty Images)

Members of the Food and Drug Administration's vaccine expert panel on Friday unanimously endorsed a booster shot for adult recipients of Johnson & Johnson's COVID-19 vaccine at least two months after the initial dose.

Why it matters: The advisory committee raised concerns about a dearth of data to support their decision but ultimately decided to support an additional shot for those over 18.